

Edgar Filing: EPIX MEDICAL INC - Form 8-K

EPIX MEDICAL INC  
Form 8-K  
February 04, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): FEBRUARY 3, 2003

EPIX MEDICAL, INC.  
(Exact name of registrant as specified in its charter)

DELAWARE	000-21863	04-3030815
-----	-----	-----
(State or other jurisdiction of	(Commission File Number) incorporation)	(IRS Employer Identification No.)

71 ROGERS STREET CAMBRIDGE, MASSACHUSETTS	02142
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (617) 250-6000  
-----

ITEM 5. OTHER EVENTS.

On February 3, 2003, the Company announced that enrollment has been completed for two MS-325 Phase III pivotal clinical trials for the detection of vascular disease in the pedal and renal arteries.

The press release announcing the enrollment for the two MS-325 Phase II clinical trials is filed as an exhibit to this Form 8-K, and is incorporated by reference into this Item 5. The foregoing description of such document and the enrollment results contemplated therein is qualified in its entirety by reference to such exhibit.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

Edgar Filing: EPIX MEDICAL INC - Form 8-K

99.1 Press Release of the Company dated February 3, 2003

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX MEDICAL, INC.  
(Registrant)

Date: February 4, 2003

/S/ PEYTON J. MARSHALL

-----  
Peyton J. Marshall  
Senior Vice-President, Finance and  
Administration, Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Press Release of the Company dated February 3, 2003